Amneal Pharmaceuticals Reprices $2.08 Billion Term Loan, Expects $12M Annual Interest Savings
AMRX has more than doubled off its 52-week low of $7.665.
Summary
Amneal Pharmaceuticals has successfully repriced its $2.08 billion term loan, reducing the interest rate margin by 50 basis points and expecting to save approximately $12 million in annualized cash interest expense.
Key Events · Financing and Capital Events · AMRX
-
Debt Repricing Completed
Amneal Pharmaceuticals LLC, a subsidiary, entered into Amendment No. 3 to its Term Loan Credit Agreement, repricing approximately $2.084 billion in term loans.
-
Interest Rate Margin Reduced
The applicable interest rate margin on the repriced term loans was reduced by 50 basis points (0.50%), to 1.50% for ABR Loans and 2.50% for Term Benchmark Loans.
-
Estimated Annual Interest Savings
The company estimates this repricing will result in approximately $12 million in annualized cash interest expense savings.
-
Maturity Date Unchanged
The stated maturity date of August 1, 2032, for the term loans remains unchanged.
Analysis · AMRX · Life Sciences
This 8-K reports a positive financial development for Amneal Pharmaceuticals. The company has repriced a significant portion of its term loan debt, lowering its interest rate margin. This move is expected to generate $12 million in annual cash interest savings, directly improving the company's profitability and cash flow. This action reflects a proactive approach to capital management and comes amidst a period of positive operational news, including recent FDA approvals and strong earnings.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRX was trading at $18.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $7.67 to $19.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.